Answers are grounded in this paper and cite their sources.
Various GPRC5D-directed agents, including bispecific antibodies (e.g., talquetamab, forimtamig) and chimeric antigen receptor T-cell (CAR-T) therapies (e.g., MCARH109, OriCAR-017, arlocabtagene autoleucel), have demonstrated rapid and durable responses in a high proportion of patients with relapsed/refractory multiple myeloma (RRMM) in phase 1 clinical trials.1-6 Across hematopoetic cells, GPRC5D is selectively expressed on MM cells, with little to no expression in normal B cells and plasma cells.
No takes yet. Share an insight, caveat, or question.
Byun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: